Showing results (1-10 of 179) with videos related to
Sort By:
Pageof 18
Future Oncology (London, England)|December 15, 2010
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancerJoel W NealClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancerJoel W Neal, Alice T ShawCurrent Treatment Options in Oncology|August 3, 2010
Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and HhJoel W Neal, Lecia V SequistTranslational Lung Cancer Research|July 18, 2017
Novel systemic therapy against malignant pleural mesotheliomaMichael R Mancuso, Joel W NealJournal of Thoracic Disease|September 16, 2021
The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancerTim Ellis-Caleo, Joel W NealThe Journal of Biological Chemistry|September 28, 2002
Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cellsJoel W Neal, Neil A ClipstoneThe Journal of Biological Chemistry|February 25, 2003
A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblastsJoel W Neal, Neil A ClipstoneClinical Advances in Hematology & Oncology : H&O|April 14, 2010
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutationsJoel W Neal, Lecia V SequistJCO Oncology Practice|December 22, 2020
Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung CancerManan P Shah, Joel W NealDrugs|April 12, 2022
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung CancerManan P Shah, Joel W NealPageof 18